Imprimis Pharmaceuticals Stock Price Down 5.3% (IMMY) Putnam Standard-11 hours ago

Imprimis Pharmaceuticals Stock Price Down 5.3% (IMMY)

Putnam Standard-11 hours ago

The Company focuses on developing and commercializing compounded drug therapies 

FDA Expectations for 503B Outsourcing Facilities, New Webinar ... EIN News (press release)-3 hours ago This segment will aid compounding pharmacies considering whether to register with the FDA as an Outsourcing Facility. It will also benefit outsourcing

FDA Expectations for 503B Outsourcing Facilities, New Webinar ...

EIN News (press release)-3 hours ago

This segment will aid compounding pharmacies considering whether to register with the FDA as an Outsourcing Facility. It will also benefit outsourcing

It looks like it is all on the doctor's back....

Senate preps for repeal vote

Politico-6 minutes ago

Physicians will have to specifically request Imprimis' compounded formulation of the drug, which, unlike Turing's product, is not FDA approved. Express Scripts ...

Express Scripts offers low-cost alternative to Turing drug By Associated Press | December 1, 2015 The nation's biggest pharmacy benefits manager is muscling back into the debate over soaring drug costs by promoting a less-expensive alternative to a life-saving medicine with a list price of $750 pe

http://www.modernhealthcare.com/article/20151201/NEWS/311309994?utm_source=modernhealthcare&utm_medium=email&utm_content=20151201-NEWS-311309994&utm_campaign=am

FDA Law Blog: The Cosmetic Modernization Amendments of 2015 Seek a Facelift for the Cosmetics Industry By Kurt R. Karst –

http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/11/the-cosmetic-modernization-amendments-of-2015-seek-a-facelift-for-the-cosmetics-industry-1.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+FdaLawBlog+%28FDA+Law+Blog%29